Cardiac contractility modulation as bailout in a patient with phospholamban p.Arg14del related cardiomyopathy intolerant to medication: a case report
We describe a case of CCM therapy in a patient with HF related to a genetic cardiomyopathy due to a pathogenic variant in phospholamban <i>(PLN)</i>, persistent symptoms despite maximally tolerated GDMT. Although it was necessary to deactivate one of the both leads due to thoracic pain, LVEF and HF symptoms significantly improved. Further research is needed to elaborate on the potential role of CCM therapy in genetic cardiomyopathies.
Authors
- Wim Huybrechts (ORCID: https://orcid.org/0000-0002-2964-8068)
- Emeline M. Van Craenenbroeck (ORCID: https://orcid.org/0000-0001-7686-2668)
- Andreas B. Gevaert (ORCID: https://orcid.org/0000-0002-1338-4133)
- Lauranne Van Assche (ORCID: https://orcid.org/0000-0002-0898-0408)
- Faro R Verelst (ORCID: https://orcid.org/0000-0001-9304-0922)
Institutions
- University of Antwerp (BE)
- Antwerp University Hospital (BE)
Publication Details
- Journal
- European Heart Journal - Case Reports
- Published
- 2024-12-24
- DOI
- https://doi.org/10.1093/ehjcr/ytae687
- Citations
- 1
- Primary Topic
- Cardiomyopathy and Myosin Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.40
Funders
- Koning Boudewijnstichting